Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Purpose
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Early Stage Triple-Negative Breast Carcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Age >= 18 years - Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 - Triple Negative Breast Cancer: - Patients with a history of stage T1cN1-2 or T2-4N0-2 breast cancer according to the primary tumor-regional lymph node anatomic staging criteria of the American Joint Committee on Cancer (AJCC), 8th edition as determined by the investigator in radiologic assessment, clinical assessment or both - Patients must have no residual invasive disease in the breast or lymph nodes after the completion of neoadjuvant therapy. Residual ductal carcinoma in situ (DCIS) is allowed. Isolated tumor cells are considered node-negative - Estrogen (ER) and progesterone (PR) =< 10%; HER2-negative by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (immunohistochemistry [IHC] and fluorescence in situ hybridization [FISH]) - If invasive disease was present in both breasts, participation in the study is permitted as long as the eligibility criteria are met for both tumors/breasts - Patients must have received neoadjuvant chemotherapy in combination with pembrolizumab for a minimum of 6 cycles. All systemic chemotherapy and ICI therapy should have been completed preoperatively - An interval of no more than 12 weeks between the completion date of the final surgery and the date of randomization * Note: Adjuvant radiation can be given on study. If given, it is encouraged to be given concurrently with pembrolizumab, per investigator discretion. Treatment with adjuvant pembrolizumab is strongly discouraged prior to participation in this trial, but if administered (e.g., if patients are awaiting pathology results), pembrolizumab may be administered for up to 6 weeks post-surgery and must be completed prior to registration - Use of investigational anti-cancer agents must be discontinued at time of registration - Adequate excision: Surgical removal of all clinically evident disease in the breast and lymph nodes as follows: - Breast surgery: Total mastectomy or breast-conserving surgery with histologically negative margins, including no ink on tumor for DCIS, at the time of excision ** For patients who undergo breast-conserving surgery, the margins of the resected specimen must be histologically free of ductal carcinoma in-situ (DCIS) as determined by the local pathologist. If pathologic examination demonstrates DCIS at the line of resection, additional operative procedures may be performed to obtain clear margins. If DCIS is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. Patients with margins positive for classic lobular carcinoma in situ (LCIS) are eligible without additional resection - Lymph node surgery: - For a patient with clinically N0 disease, a sentinel lymph node biopsy should have been performed at time of surgical evaluation, and if pathologically node positive, the patient is no longer eligible. Isolated tumor cells are considered node-negative - For a patient with clinically N1 disease at diagnosis (with positive results from a fine-needle aspiration, core biopsy, or sentinel node biopsy performed prior to preoperative therapy) additional surgical evaluation of the axilla following preoperative therapy is required *** If they become cN0 (no palpable adenopathy), then a sentinel lymph node biopsy could have been performed at time of surgery (axillary dissection would also be permitted); if the sentinel lymph node biopsy is positive, the patient is no longer eligible - If sentinel node biopsy performed before preoperative therapy was negative, no additional surgical evaluation of the axilla is required after preoperative therapy. If sentinel node biopsy performed before preoperative therapy was positive, an ALND is required after preoperative therapy - If the only sentinel node identified by isotope scan is in the internal mammary chain, surgical evaluation of the axilla is still required - If sentinel node evaluation after preoperative therapy is negative, no further additional surgical evaluation of the axilla is required - Axillary dissection without sentinel node evaluation is permitted as the initial or sole axillary evaluation after preoperative therapy - If breast-conserving surgery was performed but patient will not be receiving breast radiation, the patient is not eligible - Not pregnant and not nursing, because this study involves an agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative serum or urine pregnancy test done =< 7 days prior to randomization is required - Absolute neutrophil count (ANC) >= 1,000/mm^3 - Platelet Count >= 100,000/mm^3 - Estimated glomerular filtration rate (eGFR) >= 15 mL/min/1.73m^2 - Total Bilirubin =<1.5 x upper limit of normal (ULN) * Patients with Gilbert's disease with a total bilirubin =< 2.5 x ULN and direct bilirubin within normal limits are permitted - Aspartate aminotransferase (AST) serum aspartate aminotransferase [SGOT] / alanine aminotransferase (ALT) serum glutamic pyruvic transaminase [SGPT] =< 3 x institutional ULN - Patients must be willing to provide tumor tissue from the diagnostic core biopsy. If inadequate tumor tissue is available, patients are still eligible to participate in the trial - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
Exclusion Criteria
- No stage IV (metastatic) breast cancer - No history of any prior (ipsi- or contralateral) invasive breast cancer. Prior DCIS is allowed - No evidence of recurrent disease following preoperative therapy and surgery - No known active liver disease, e.g. due to hepatitis B virus (HBV), hepatitis C virus (HCV), autoimmune hepatic disorders, or sclerosing cholangitis - No history of intolerance, including Grade 3 or 4 infusion reaction or hypersensitivity to pembrolizumab or murine proteins or any components of the product * Note: Prior immune-related adverse events (irAEs) are allowed if they resolved and the patient tolerated subsequent therapy without requiring chronic steroids for the irAE - No medical conditions that require chronic systemic steroids (>10 mg prednisone daily or equivalent) or any other form of immunosuppressive medications and has required such therapy in the last two years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic therapy - Patients who are unable or unwilling to comply with the requirements of the protocol per investigator assessment are not eligible
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Arm I (pembrolizumab) |
Patients receive pembrolizumab IV on study. Patients also undergo tumor biopsy on study, and collection of blood on study and during follow-up. |
|
Experimental Arm II (observation) |
Patients undergo observation on study. Patients also undergo tumor biopsy on study, and collection of blood on study and during follow-up. |
|
Recruiting Locations
Birmingham, Alabama 35233
Fairhope, Alabama 36532
Site Public Contact
251-435-4584
Mobile, Alabama 36607
Site Public Contact
251-435-3942
Kingman, Arizona 86401
Phoenix, Arizona 85004
Phoenix, Arizona 85054
Site Public Contact
855-776-0015
Fayetteville, Arkansas 72703
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Rogers, Arkansas 72758
Springdale, Arkansas 72762
Arroyo Grande, California 93420
Beverly Hills, California 90211
Cameron Park, California 95682
Dublin, California 94568
Site Public Contact
877-642-4691
Fremont, California 94538
Fresno, California 93720
Los Angeles, California 90048
Site Public Contact
310-423-8965
Marysville, California 95901
Site Public Contact
530-749-4400
Modesto, California 95356
Oakland, California 94611
Palm Springs, California 92262
Site Public Contact
760-416-4730
Palo Alto, California 94304
Pasadena, California 91105
Site Public Contact
626-535-2420
Roseville, California 95661
Sacramento, California 95814
Sacramento, California 95817
Site Public Contact
916-734-3089
Sacramento, California 95823
Salinas, California 93901
San Francisco, California 94110
San Francisco, California 94115
San Jose, California 95119
San Jose, California 95124
San Leandro, California 94577
San Rafael, California 94903
Santa Clara, California 95051
Santa Monica, California 90404
Site Public Contact
310-582-7448
Santa Rosa, California 95403
South San Francisco, California 94080
Tarzana, California 91356
Site Public Contact
818-981-3818
Torrance, California 90505
Truckee, California 96161
Site Public Contact
530-582-6450
Vallejo, California 94589
Walnut Creek, California 94596
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Colorado Springs, Colorado 80909
Site Public Contact
719-365-2406
Colorado Springs, Colorado 80920
Site Public Contact
719-364-6700
Denver, Colorado 80205
Denver, Colorado 80206
Highlands Ranch, Colorado 80129
Site Public Contact
720-848-0650
Lafayette, Colorado 80026
Lone Tree, Colorado 80124
Lone Tree, Colorado 80124
Danbury, Connecticut 06810
Site Public Contact
203-739-8074
Derby, Connecticut 06418
Fairfield, Connecticut 06824
Glastonbury, Connecticut 06033
Greenwich, Connecticut 06830
Guilford, Connecticut 06437
Hartford, Connecticut 06105
New Haven, Connecticut 06520
North Haven, Connecticut 06473
Norwalk, Connecticut 06856
Stamford, Connecticut 06902
Torrington, Connecticut 06790
Trumbull, Connecticut 06611
Waterbury, Connecticut 06708
Waterford, Connecticut 06385
Newark, Delaware 19713
Newark, Delaware 19713
Rehoboth Beach, Delaware 19971
Washington, District of Columbia 20007
Site Public Contact
202-444-2223
Washington, District of Columbia 20010
Site Public Contact
202-877-8839
Clearwater, Florida 33756
Site Public Contact
855-314-8646
Gainesville, Florida 32610
Jacksonville, Florida 32224-9980
Site Public Contact
855-776-0015
Orlando, Florida 32806
Pembroke Pines, Florida 33028
Site Public Contact
954-265-4325
Safety Harbor, Florida 34695
Tallahassee, Florida 32308
Site Public Contact
850-431-0673
Tampa, Florida 33606
Tampa, Florida 33607
Albany, Georgia 31701
Atlanta, Georgia 30303
Site Public Contact
404-489-9164
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Atlanta, Georgia 30342
Augusta, Georgia 30901
Site Public Contact
706-821-2944
Augusta, Georgia 30909
Site Public Contact
706-736-1830
Duluth, Georgia 30096
Lawrenceville, Georgia 30046
'Aiea, Hawaii 96701
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
Site Public Contact
808-532-0315
Honolulu, Hawaii 96813
Site Public Contact
808-545-8548
Honolulu, Hawaii 96813
Site Public Contact
808-522-4333
Honolulu, Hawaii 96817
Site Public Contact
808-531-8521
Honolulu, Hawaii 96819
Honolulu, Hawaii 96826
Site Public Contact
808-983-6090
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Fruitland, Idaho 83619
Meridian, Idaho 83642
Nampa, Idaho 83686
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Twin Falls, Idaho 83301
Barrington, Illinois 60010
Site Public Contact
847-842-4847
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Centralia, Illinois 62801
Chicago, Illinois 60611
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Chicago, Illinois 60637
Chicago, Illinois 60657
Site Public Contact
773-296-5360
Crystal Lake, Illinois 60014
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Downers Grove, Illinois 60515
Effingham, Illinois 62401
Elgin, Illinois 60123
Site Public Contact
847-429-2907
Eureka, Illinois 61530
Galesburg, Illinois 61401
Harvey, Illinois 60426
Hazel Crest, Illinois 60429
Site Public Contact
708-799-9995
Kewanee, Illinois 61443
Libertyville, Illinois 60048
Libertyville, Illinois 60048
Macomb, Illinois 61455
Mattoon, Illinois 61938
Moline, Illinois 61265
Site Public Contact
309-779-2000
New Lenox, Illinois 60451
O'Fallon, Illinois 62269
Oak Lawn, Illinois 60453-2699
Site Public Contact
800-323-8622
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Park Ridge, Illinois 60068
Site Public Contact
847-384-3621
Pekin, Illinois 61554
Peoria, Illinois 61615
Peru, Illinois 61354
Princeton, Illinois 61356
Rockford, Illinois 61108
Site Public Contact
815-227-2633
Rockford, Illinois 61114
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Washington, Illinois 61571
Avon, Indiana 46123
Carmel, Indiana 46032
Crown Point, Indiana 46307
Site Public Contact
219-310-2550
Dyer, Indiana 46311
Site Public Contact
219-924-8178
Hobart, Indiana 46342
Site Public Contact
219-947-1795
Hobart, Indiana 46342
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
Indianapolis, Indiana 46312
Munster, Indiana 46321
Site Public Contact
219-836-3349
Munster, Indiana 46321
Valparaiso, Indiana 46383
Cedar Rapids, Iowa 52402
Site Public Contact
319-297-2900
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Council Bluffs, Iowa 51503
Site Public Contact
712-322-4136
Council Bluffs, Iowa 51503
Iowa City, Iowa 52242
Site Public Contact
800-237-1225
Chanute, Kansas 66720
Dodge City, Kansas 67801
El Dorado, Kansas 67042
Hays, Kansas 67601
Site Public Contact
785-623-5774
Independence, Kansas 67301
Kansas City, Kansas 66160
Kingman, Kansas 67068
Lawrence, Kansas 66044
Liberal, Kansas 67905
McPherson, Kansas 67460
Newton, Kansas 67114
Olathe, Kansas 66061
Overland Park, Kansas 66209
Overland Park, Kansas 66210
Overland Park, Kansas 66211
Parsons, Kansas 67357
Pratt, Kansas 67124
Salina, Kansas 67401
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Wellington, Kansas 67152
Westwood, Kansas 66205
Wichita, Kansas 67208
Wichita, Kansas 67214
Wichita, Kansas 67214
Winfield, Kansas 67156
Lexington, Kentucky 40536
Site Public Contact
859-257-3379
Covington, Louisiana 70433
New Orleans, Louisiana 70121
Annapolis, Maryland 21401
Bethesda, Maryland 20889-5600
Site Public Contact
301-319-2100
Frederick, Maryland 21702
Site Public Contact
301-668-7043
Boston, Massachusetts 02111
Boston, Massachusetts 02118
Site Public Contact
617-638-8265
Boston, Massachusetts 02215
Site Public Contact
877-442-3324
Ann Arbor, Michigan 48106
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Brighton, Michigan 48114
Canton, Michigan 48188
Canton, Michigan 48188
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Clinton Township, Michigan 48038
Detroit, Michigan 48202
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49009
Livonia, Michigan 48154
Muskegon, Michigan 49444
Norton Shores, Michigan 49444
Novi, Michigan 48374
Pontiac, Michigan 48341
Reed City, Michigan 49677
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Southfield, Michigan 48075
Traverse City, Michigan 49684
Wyoming, Michigan 49519
Ypsilanti, Michigan 48106
Ypsilanti, Michigan 48197
Bemidji, Minnesota 56601
Burnsville, Minnesota 55337
Coon Rapids, Minnesota 55433
Edina, Minnesota 55435
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Rochester, Minnesota 55905
Site Public Contact
855-776-0015
Saint Cloud, Minnesota 56303
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Columbus, Mississippi 39705
Grenada, Mississippi 38901
Jackson, Mississippi 39216
Site Public Contact
601-815-6700
New Albany, Mississippi 38652
Oxford, Mississippi 38655
Southhaven, Mississippi 38671
Cape Girardeau, Missouri 63703
Columbia, Missouri 65212
Site Public Contact
573-882-7440
Creve Coeur, Missouri 63141
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Independence, Missouri 64057
Kansas City, Missouri 64108
Site Public Contact
816-404-4375
Kansas City, Missouri 64111
Kansas City, Missouri 64132
Kansas City, Missouri 64154
Lee's Summit, Missouri 64064
Lee's Summit, Missouri 64086
North Kansas City, Missouri 64116
Saint Joseph, Missouri 64506
Saint Louis, Missouri 63110
Saint Louis, Missouri 63129
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63136
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Saint Peters, Missouri 63376
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Missoula, Montana 59804
Bellevue, Nebraska 68123
Omaha, Nebraska 68114
Site Public Contact
402-334-4773
Omaha, Nebraska 68114
Site Public Contact
402-354-5144
Omaha, Nebraska 68114
Omaha, Nebraska 68118
Site Public Contact
402-559-5600
Omaha, Nebraska 68198
Henderson, Nevada 89052
Las Vegas, Nevada 89102
Las Vegas, Nevada 89148
Concord, New Hampshire 03301
Site Public Contact
603-224-2556
Manchester, New Hampshire 03103
Site Public Contact
800-339-6484
Englewood, New Jersey 07631
Site Public Contact
201-894-3456
Hackensack, New Jersey 07601
Site Public Contact
201-996-2879
Mullica Hill, New Jersey 08062
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87110
Rio Rancho, New Mexico 87124
Buffalo, New York 14263
East Syracuse, New York 13057
Site Public Contact
315-472-7504
Mineola, New York 11501
New York, New York 10011
New York, New York 10016
New York, New York 10029
Rochester, New York 14623
Rochester, New York 14642
Site Public Contact
585-275-5830
Stony Brook, New York 11794
Site Public Contact
800-862-2215
Webster, New York 14580
Asheboro, North Carolina 27203
Burlington, North Carolina 27215
Cary, North Carolina 27518
Chapel Hill, North Carolina 27599
Charlotte, North Carolina 28204
Garner, North Carolina 27529
Greensboro, North Carolina 27403
Greensboro, North Carolina 27410
Greenville, North Carolina 27834
Hendersonville, North Carolina 28791
Huntersville, North Carolina 28078
Huntersville, North Carolina 28078
Kernersville, North Carolina 27284
Matthews, North Carolina 28105
Mooresville, North Carolina 28117
Mount Airy, North Carolina 27030
Pinehurst, North Carolina 28374
Raleigh, North Carolina 27607
Raleigh, North Carolina 27614
Reidsville, North Carolina 27320
Salisbury, North Carolina 28144
Salisbury, North Carolina 28144
Thomasville, North Carolina 27360
Washington, North Carolina 27889
Winston-Salem, North Carolina 27103
Bismarck, North Dakota 58501
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Akron, Ohio 44304
Barberton, Ohio 44203
Belpre, Ohio 45714
Centerville, Ohio 45459
Chillicothe, Ohio 45601
Cincinnati, Ohio 45220
Columbus, Ohio 43210
Columbus, Ohio 43213
Columbus, Ohio 43219
Dayton, Ohio 45409
Site Public Contact
937-276-8320
Dayton, Ohio 45415
Dayton, Ohio 45415
Franklin, Ohio 45005-1066
Grove City, Ohio 43123
Kettering, Ohio 45429
Lancaster, Ohio 43130
Marysville, Ohio 43040
Medina, Ohio 44256
Newark, Ohio 43055
Perrysburg, Ohio 43551
Portsmouth, Ohio 45662
Springfield, Ohio 45504
Sylvania, Ohio 43560
Toledo, Ohio 43623
Toledo, Ohio 43623
Site Public Contact
800-444-3561
Troy, Ohio 45373
Westerville, Ohio 43081
Zanesville, Ohio 43701
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73120
Site Public Contact
405-752-3402
Clackamas, Oregon 97015
Clackamas, Oregon 97015
Gresham, Oregon 97030
Site Public Contact
503-413-2150
Newberg, Oregon 97132
Ontario, Oregon 97914
Oregon City, Oregon 97045
Portland, Oregon 97210
Portland, Oregon 97213
Portland, Oregon 97225
Portland, Oregon 97227
Tualatin, Oregon 97062
Site Public Contact
503-413-1742
Allentown, Pennsylvania 18103
Bethlehem, Pennsylvania 18017
Danville, Pennsylvania 17822
East Stroudsburg, Pennsylvania 18301
Sayre, Pennsylvania 18840
Site Public Contact
800-836-0388
Scranton, Pennsylvania 18510
Wilkes-Barre, Pennsylvania 18711
Willow Grove, Pennsylvania 19090
Providence, Rhode Island 02903
Site Public Contact
401-444-1488
Providence, Rhode Island 02905
Site Public Contact
401-274-1122
Westerly, Rhode Island 02891
Georgetown, South Carolina 29440
Greenville, South Carolina 29601
Greenville, South Carolina 29607
Greenwood, South Carolina 29646
West Columbia, South Carolina 29169
Aberdeen, South Dakota 57401
Pierre, South Dakota 57501
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57105
Sioux Falls, South Dakota 57117-5134
Collierville, Tennessee 38017
Knoxville, Tennessee 37920
Site Public Contact
865-544-9773
Memphis, Tennessee 38120
Baytown, Texas 77521
Conroe, Texas 77384
Dallas, Texas 75235
Dallas, Texas 75237
Dallas, Texas 75390
Fort Worth, Texas 76104
Fort Worth, Texas 76104
Houston, Texas 77030
Site Public Contact
713-790-2700
Houston, Texas 77030
Houston, Texas 77070
Houston, Texas 77079
Houston, Texas 77094
Site Public Contact
832-522-2873
League City, Texas 77573
Nassau Bay, Texas 77058
Richardson, Texas 75080
Sugar Land, Texas 77478
Sugar Land, Texas 77479
Site Public Contact
281-242-2873
The Woodlands, Texas 77385
Fairfax, Virginia 22031
Fairfax, Virginia 22033
Falls Church, Virginia 22042
Mechanicsville, Virginia 23116
Midlothian, Virginia 23114
Richmond, Virginia 23226
Richmond, Virginia 23235
Richmond, Virginia 23298
Renton, Washington 98055
Vancouver, Washington 98684
Vancouver, Washington 98686
Site Public Contact
503-413-2150
Yakima, Washington 98902
Huntington, West Virginia 25701
Antigo, Wisconsin 54409
Appleton, Wisconsin 54911
Berlin, Wisconsin 54923
Burlington, Wisconsin 53105
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54311
Janesville, Wisconsin 53548
Johnson Creek, Wisconsin 53038
Kenosha, Wisconsin 53142
Madison, Wisconsin 53792
Marinette, Wisconsin 54143
Medford, Wisconsin 54451
Menomonee Falls, Wisconsin 53051
Site Public Contact
262-257-5100
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Milwaukee, Wisconsin 53233
Mukwonago, Wisconsin 53149
Neenah, Wisconsin 54956
New London, Wisconsin 54961
Oak Creek, Wisconsin 53154
Site Public Contact
414-805-0505
Oconomowoc, Wisconsin 53066
Site Public Contact
262-928-7878
Oshkosh, Wisconsin 54904
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53406
Rhinelander, Wisconsin 54501
Shawano, Wisconsin 54166
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54481
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Waukesha, Wisconsin 53188
Waupaca, Wisconsin 54981
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
West Bend, Wisconsin 53095
Site Public Contact
414-805-0505
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
Manati, Puerto Rico 00674
Site Public Contact
787-621-4397
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00936
Site Public Contact
787-763-1296
More Details
- NCT ID
- NCT05812807
- Status
- Recruiting
- Sponsor
- Alliance for Clinical Trials in Oncology
Detailed Description
PRIMARY OBJECTIVES: I. To evaluate whether observation results in a non-inferior recurrence-free survival (RFS) compared to adjuvant pembrolizumab in early-stage triple-negative breast cancer (TNBC) patients who achieve a pathologic complete response (pCR) after neoadjuvant chemotherapy with pembrolizumab. II. To compare quality of life (QOL) at approximately 27 weeks as assessed by the Functional Assessment of Cancer Therapy-Breast (FACT-B) Trial Outcome Index between patients randomized to adjuvant pembrolizumab versus observation. (Quality of Life) III. To assess the social value of de-escalation of adjuvant breast cancer immunotherapy at approximately 27 weeks and, by modeling, over a lifetime. (Value of Care) SECONDARY OBJECTIVES: I. To evaluate whether observation compared to adjuvant pembrolizumab impacts the following: Ia. RFS by stage at presentation and by receipt of prior anthracycline therapy; Ib. Adverse event rate: difference in Grade 3 or higher adverse event rates overall and Grade 3 or higher immune-related adverse events (irAEs) rates; Ic. Overall Survival (OS); Id. Locoregional recurrence (LRR both isolated LRR as first events and LRR events simultaneous with DM); Ie. RFS, LRR, OS, adverse events, and QOL by age (=< 45, 46-65, and > 65), race, and ethnicity; If. Adverse events related to receipt of radiotherapy. II. To assess the value of de-escalation of breast cancer immunotherapy from the payer perspective at approximately 27 weeks and, by modelling, over a lifetime. (Value of Care) III. To compare patient out-of-pocket costs at approximately 27 weeks between patients randomized to adjuvant pembrolizumab versus observation. (Value of Care) IV. To compare financial toxicity at approximately 27 weeks between patients randomized to adjuvant pembrolizumab versus observation. (Value of Care) V. To compare work/productivity impairment at approximately 27 weeks between patients randomized to adjuvant pembrolizumab versus observation. (Value of Care) EXPLORATORY OBJECTIVES: I. To describe trajectories of QOL over time among patients randomized to adjuvant pembrolizumab versus (vs.) observation. (Quality of Life) II. To compare various QOL domains after approximately 27 weeks as assessed by the 5 subscales of the FACT-B Index between patients randomized to adjuvant pembrolizumab versus observation. (Quality of Life) III. To compare self-reported symptomatic adverse events at approximately 27 weeks assessed by the patient reported outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE) between patients randomized to adjuvant pembrolizumab versus observation. (Quality of Life) IV. To describe trajectories of financial toxicity and work/productivity impairment over time from baseline to approximately 27 weeks among patients randomized to adjuvant pembrolizumab versus observation. (Value of Care) V. To develop and assess a measure of value from the patient perspective at approximately 27 weeks. (Value of Care) OUTLINE: Patients are randomized to 1 of 2 arms after completing neoadjuvant chemotherapy in combination with pembrolizumab, followed by definitive breast surgery. ARM I (PEMBROLIZUMAB): Patients receive pembrolizumab intravenously (IV) on study. Patients also undergo tumor biopsy on study, and collection of blood on study and during follow-up. ARM II (OBSERVATION): Patients undergo observation on study. Patients also undergo tumor biopsy on study, and collection of blood on study and during follow-up.